<p><em>联邦陪审团在为期两周的审判后，裁定对对冲基金及两名高管的所有指控无罪</em></p>
<p>, /PRNewswire/ -- 加州联邦陪审团周二对 Armistice Capital LLC、Armistice Capital Master Fund Ltd.、创始人 Steven Boyd 和董事总经理 Keith Maher 作出了完全的辩护裁决，清除了所有被告在 Vaxart Inc. 投资者提起的证券欺诈和内幕交易指控。</p>
<p>该裁决是在两天内不到四小时的审议后作出的，结束了于 4 月 14 日在加州北区美国地方法院由美国地方法官 Vince Chhabria 主持的审判。</p>
<p>原告声称，Armistice 在 COVID-19 大流行期间操纵了 Vaxart 股票的市场，通过利用虚假和误导性的新闻稿以人为抬高的价格出售其持仓，并且 Boyd 和 Armistice 在出售时掌握了重要的非公开信息。被告在整个诉讼过程中否认了所有指控。</p>
<p>辩护律师 Charles Connolly 来自 Akin Gump Strauss Hauer &amp; Feld LLP 在审判中辩称，原告的案件基于孤立的短语，而不是 Vaxart 新闻稿的完整内容，这些内容是准确和真实的，并且没有证据表明 Armistice、Boyd 或 Maher 在新闻稿发布之前知道任何信息。&#34;一个理性的投资者不会只看标题，&#34; Connolly 说。</p>
<p>案件 <em>In re: Vaxart Inc. Securities Litigation</em>，案件编号 3:20-cv-05949，起源于 Armistice 在 2020 年 6 月 26 日和 6 月 29 日执行的股票销售，此前 Vaxart 宣布了一项制造协议以及公司被纳入联邦政府的 “快速行动计划”。Vaxart 及其现任和前任高管在原告投诉中被列为共同被告，于 2022 年单独和解，金额为 1200 万美元。</p>
<p>Armistice Capital 的代表律师包括 Akin Gump Strauss Hauer &amp; Feld LLP 的 Joshua A. Rubin、Lillian J. Rand、Charles F. Connolly、Stacey H. Mitchell、Kaitlin D. Shapiro 和 David M. Giller。</p>
<p><strong>媒体联系人：</strong> Steven Boyd，Armistice Capital 管理合伙人，510 Madison Avenue，New York, NY, 10022，(212) 231-4930 [email protected]</p>
<p>来源 Armistice Capital</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REE1OTI2OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQwOTA2UFJfTkVXU19VU1BSX19fX19EQTU5MjY4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REE1OTI2OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQwOTA2UFJfTkVXU19VU1BSX19fX19EQTU5MjY4"/></p>

VXRT

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

<p>加利福尼亚州的一陪审团对 Armistice Capital LLC 及其高管作出了完全的辩护裁决，清除了他们在 Vaxart Inc.投资者提起的证券集体诉讼中的所有指控。陪审团在为期两周的审判后，经过不到四小时的审议，作出了裁决。原告指控市场操纵和内幕交易，辩方则认为这些指控基于孤立的短语，并且新闻稿是准确的。此案源于 Armistice 在 2020 年 Vaxart 公告后进行的股票销售。Vaxart 在 2022 年单独达成了 1200 万美元的和解</p>

<p><em>Federal jury clears hedge fund and two executives of all claims following two-week trial</em></p>
<div class="lb-trans"><p><em>联邦陪审团在为期两周的审判后，裁定对对冲基金及两名高管的所有指控无罪</em></p>
</div><p>, /PRNewswire/ -- A California federal jury on Tuesday returned a complete defense verdict in favor of Armistice Capital LLC, Armistice Capital Master Fund Ltd., founder Steven Boyd, and Managing Director Keith Maher, clearing all defendants of securities fraud and insider trading claims brought by a class of Vaxart Inc. investors.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 加州联邦陪审团周二对 Armistice Capital LLC、Armistice Capital Master Fund Ltd.、创始人 Steven Boyd 和董事总经理 Keith Maher 作出了完全的辩护裁决，清除了所有被告在 Vaxart Inc. 投资者提起的证券欺诈和内幕交易指控。</p>
</div><p>The verdict came after less than four hours of deliberation over two days, concluding a trial that began April 14 in the U.S. District Court for the Northern District of California before U.S. District Judge Vince Chhabria.</p>
<div class="lb-trans"><p>该裁决是在两天内不到四小时的审议后作出的，结束了于 4 月 14 日在加州北区美国地方法院由美国地方法官 Vince Chhabria 主持的审判。</p>
</div><p>Plaintiffs had alleged that Armistice manipulated the market for Vaxart shares during the COVID-19 pandemic by leveraging false and misleading press releases to sell its position at artificially inflated prices, and that Boyd and Armistice possessed material nonpublic information at the time of sale. The defendants denied all allegations throughout the proceedings.</p>
<div class="lb-trans"><p>原告声称，Armistice 在 COVID-19 大流行期间操纵了 Vaxart 股票的市场，通过利用虚假和误导性的新闻稿以人为抬高的价格出售其持仓，并且 Boyd 和 Armistice 在出售时掌握了重要的非公开信息。被告在整个诉讼过程中否认了所有指控。</p>
</div><p>Defense counsel Charles Connolly of Akin Gump Strauss Hauer &amp; Feld LLP argued at trial that the plaintiffs' case rested on isolated phrases rather than the full content of the Vaxart press releases, which were accurate and true, and that there was no evidence that Armistice, Boyd or Maher knew anything about the information in the press releases until after they were issued. &#34;A reasonable investor does not just read the headlines,&#34; Connolly said.</p>
<div class="lb-trans"><p>辩护律师 Charles Connolly 来自 Akin Gump Strauss Hauer &amp; Feld LLP 在审判中辩称，原告的案件基于孤立的短语，而不是 Vaxart 新闻稿的完整内容，这些内容是准确和真实的，并且没有证据表明 Armistice、Boyd 或 Maher 在新闻稿发布之前知道任何信息。&#34;一个理性的投资者不会只看标题，&#34; Connolly 说。</p>
</div><p>The case, <em>In re: Vaxart Inc. Securities Litigation</em>, case number 3:20-cv-05949, had its origins in stock sales Armistice executed on June 26 and June 29, 2020, following Vaxart announcements about a manufacturing agreement and the company's inclusion in the federal government's Operation Warp Speed program. Vaxart and its current and former executives, named as co-defendants in the original complaint, settled separately in 2022 for $12 million.</p>
<div class="lb-trans"><p>案件 <em>In re: Vaxart Inc. Securities Litigation</em>，案件编号 3:20-cv-05949，起源于 Armistice 在 2020 年 6 月 26 日和 6 月 29 日执行的股票销售，此前 Vaxart 宣布了一项制造协议以及公司被纳入联邦政府的 “快速行动计划”。Vaxart 及其现任和前任高管在原告投诉中被列为共同被告，于 2022 年单独和解，金额为 1200 万美元。</p>
</div><p>Armistice Capital was represented by Joshua A. Rubin, Lillian J. Rand, Charles F. Connolly, Stacey H. Mitchell, Kaitlin D. Shapiro, and David M. Giller of Akin Gump Strauss Hauer &amp; Feld LLP.</p>
<div class="lb-trans"><p>Armistice Capital 的代表律师包括 Akin Gump Strauss Hauer &amp; Feld LLP 的 Joshua A. Rubin、Lillian J. Rand、Charles F. Connolly、Stacey H. Mitchell、Kaitlin D. Shapiro 和 David M. Giller。</p>
</div><p><strong>Media Contact:</strong> Steven Boyd, Managing Partner, Armistice Capital, 510 Madison Avenue, New York, NY, 10022, (212) 231-4930 [email protected]</p>
<div class="lb-trans"><p><strong>媒体联系人：</strong> Steven Boyd，Armistice Capital 管理合伙人，510 Madison Avenue，New York, NY, 10022，(212) 231-4930 [email protected]</p>
</div><p>SOURCE Armistice Capital</p>
<div class="lb-trans"><p>来源 Armistice Capital</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REE1OTI2OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQwOTA2UFJfTkVXU19VU1BSX19fX19EQTU5MjY4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DA59268&amp;Transmission_Id=202605140906PR_NEWS_USPR_____DA59268&amp;DateId=20260514"/></p>

09:06 ETJury Returns Full Defense Verdict for Armistice Capital and Its Executives in Vaxart Securities Class Action

prnewswire

Vaxart

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

基因改革 ETF - ARK

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

Invesco Nasdaq Biotechnology ETF

动态生物技术与基因组 ETF - Invesco

陪审团在 Vaxart 证券集体诉讼案中为 Armistice Capital 及其高管做出了全面无罪裁决